Ann: Glaucoma Sales update, page-22

EYE has higher revenue (and now thanks to the new device, higher growth) than many companies with much higher market caps. Even more, we still have an exciting R&D pipeline offering future growth opportunities, including 2RT which is (imo) an incredibly exciting, speculative, opportunity (regardless of the probability of it coming to fruition).

The reason for EYE being so significantly undervalued relative to so many other stocks (in both the MIGS segment and the broader market) is hard to tell. I'd say the main reason though is a lack of understanding and knowledge about this company. I'm willing to bet (with my decent sized position) that iTrack Advance financial performance will get this company in the spotlight so that it is actually researched, but who knows. Time will tell what happens, and by this time next year we should know for sure whether our patience has been worth it.